Prescribers without outpatient panels were more likely than endocrinologists to prescribe second-generation diabetes drugs (SGLT-2 inhibitors: RR, 2.69 [95% CI, 1.68-4.30]; P < .001; DPP-4 inhibitors: RR, 1.98 [95% CI, 1.85-2.13]; P < .001; GLP-1 receptor agonists: RR, 2.70 [95% CI, 2.03-3.59]; P < .001). This evidence concerns the gene DPP4 and diabetes mellitus.